Abstract:Purpose: Early-stage head and neck cancer patients are at high risks for tumor recurrence and secondary primary tumor (SPT) development. We hypothesized that latent genetic instability and proliferation potential may be associated with elevated risks of SPT and recurrence. Experimental Design: We conducted a nested case-control study within a randomized, placebo-controlled chemoprevention trial in patients with early-stage head and neck cancer. We compared prediagnostic bleomycin-induced chromatid breaks in peripheral blood lymphocyte cultures (as an indicator of latent genetic instability) between 298 cases (patients with SPT/recurrence) and 693 controls (patients without SPT/recurrence). We also determined the joint effects of latent genetic instability and elevated proliferation potential [indicated by serum insulin-like growth factor (IGF) level] in modulating the risk of SPT and recurrence. Results: In the Cox proportional hazards model, patients with higher mutagen sensitivity (using a cutoff of ≥0.50 breaks per cell) exhibited a significantly increased risk of developing SPT/recurrence [hazard ratio, 1.38; 95% confidence interval (95% CI), 1.02-1.86]. Cases also exhibited significantly higher levels of IGF-I and IGF-binding protein-3 than controls (P = 0.022 and 0.042, respectively). Moreover, there were joint effects between mutagen sensitivity and IGFs in modulating SPT/recurrence risk. Using patients with low IGF-I level and low mutagen sensitivity profile as the reference group, the odds ratios of developing SPT/recurrence for patients with high IGF-I level alone, high mutagen sensitivity alone, and both high IGF-I level and high mutagen sensitivity were 2.85 (95% CI, 0.92-8.82), 3.92 (95% CI, 1.28-11.97), and 6.16 (95% CI, 2.03-18.71), respectively. A similar joint effect was observed for mutagen sensitivity and IGF-binding protein-3 level. Conclusions: This is the largest prospective study to evaluate mutagen sensitivity as a prognosis marker in head and neck cancer because mutagen sensitivity data were derived from baseline samples drawn before the development of SPT or tumor recurrence. The results also show for the first time that latent genetic instability and elevated proliferation potential jointly elevate the risk of second tumors in early-stage head and neck cancers.

Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer

Associations Between Genetic Polymorphisms of Glutathione S-transferase M1 and T1,smoking and Susceptibility to Colorectal Cancer:A Case-Control Study

RETRACTED ARTICLE: Glutathione S -transferase P1 gene Ile105Val polymorphism might be associated with lung cancer risk in the Chinese Han population

Glutathione S-Transferase T1 Null Genotype is Associated with Susceptibility to Inflammatory Bowel Disease

Glutathione S-transferase M1, T1, and P1 polymorphisms and risk of glioma: a meta-analysis

GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients

Glutathione S-transferase M1 polymorphism and the risk on colorectal cancer: a multilevel meta regression]

STUDY ON THE METHYLATION OF P16 GENE AND GENETIC POLYMORPHISM OF GSTM1 GENE RELATED WITH SUSCEPTIBILITY TO NON-SMALL CELL LUNG CANCER

Quantitative assessment of the association between glutathione S-transferase M1 polymorphism and the risk of developing nasopharyngeal cancer

GSTM1 Copy Number and Promoter Haplotype As Predictors for Risk of Recurrence And/or Second Primary Tumor in Patients with Head and Neck Cancer

Association Of The Glutathione S-Transferase M1, T1 Polymorphisms With Cancer: Evidence From A Meta-Analysis

Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to head and neck carcinoma: a systematic review with five analyses

Genetic Polymorphisms in Glutathione-S-Transferase Genes (gstm1, Gstt1, Gstp1) and Survival after Chemotherapy for Invasive Breast Carcinoma

Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer

Quantitative Assessment of the Effect of Glutathione S -Transferase Genes GSTM1 and GSTT1 on Hepatocellular Carcinoma Risk

Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.

Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States)

Genetic Polymorphisms Of Glutathione S-Transferase Genes Gstm1, Gstt1 And Risk Of Hepatocellular Carcinoma

Glutathione S-Transferase M1 Polymorphism and Breast Cancer Susceptibility: A Meta-Analysis Involving 46,281 Subjects

Abstract 885:GSTM1CNV and Promoter SNPs Are Associated with REC/SPT and Survival after Retinoid Acid Treatment for Head and Neck Cancer

Genetic Polymorphisms in Glutathione S-Transferase (GST) Gene and Their Correlation with Toxicity of Chemotherapy in Breast Cancer Patients